Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDXK | O00764 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897041 | 0.83 | ADORA2A (0.36) | FDPSADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL13059042 | 0.79 | ADORA2A (0.34) | FDPSADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL31332871 | 0.79 | MEN1 (0.33) | FDPS | |
| Hydrochloric Acid SCHEMBL858871 | 0.78 | ADORA2A (0.33) | FDPSADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL31332840 | 0.78 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL31333034 | 0.78 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL861750 | 0.78 | NPSR1 (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3579547 | 0.77 | CSNK2A2 (0.42) | FDPSALDH1A1 | |
| SCHEMBL31332943 | 0.75 | ADORA2A (0.32) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11211782 | 0.74 | CYP11B1 (0.47) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | Wuxi Life Fountain Biotech Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-3988098-A1 | HETEROCYCLO ALKYL COMPOUNDS USED AS CCR2/CCR5 ANTAGONIST | Shenzhen Lingfang Biotech Co., Ltd (CN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| CN-102414241-A | Microencapsulated composition containing imidazole compound, curable composition using same, and masterbatch-type curing agent | ASAHI KASEI E MATERIALS CORP | 2012-04-11 | — | — | CN | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | FDPS 116/4885ADORA2A 101/4885ADORA1 82/4885 |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | FDPS 3366/4885ADORA2A 410/4885ADORA1 700/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | FDPS 3366/4885ADORA2A 410/4885ADORA1 700/4885 |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | CCR2, CCR5, CCRL2 | FDPS 2621/4885ADORA2A 500/4885ADORA1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.